A genome-wide linkage scan has identified the chromosome 17p11.2-q11.2 region as the susceptibility locus for fibromyalgia.
Analysis of claims data finds patients often receive starting doses of Butrans that do not follow published recommendations, with more than one-third of patients receiving initial doses that are too low.
Pain has been associated with a number of conditions, including addiction, depression, and anxiety. Greater awareness of concurrent comorbid conditions and the options available to treat them produces better outcomes in chronic pain patients.
The advent of accountable care organizations, bundled payments, and other reforms under the Affordable Care Act has steered the focus of health care delivery from quantity to quality, but where exactly do pain medicine providers fit into the new value-based care model, and how can it benefit their patients?
As more than 60 percent of women with temporomandibular disorders (TMD) also exhibit abdominal pain consistent with irritable bowel syndrome (IBS) symptoms, two researchers in the neural and pain sciences department of the University of Maryland School of Dentistry, in Baltimore, have developed a model to better illustrate the two conditions’ comorbidity.
Low-dose naltrexone treatment is associated with significant reductions in pain in patients with fibromyalgia, according to a study published in the February issue of Arthritis & Rheumatism.